Last updated on May 2020

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease


Brief description of study

The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.

Clinical Study Identifier: NCT03623321

Find a site near you

Start Over

Syrentis Clinical Research

Santa Ana, CA United States
  Connect »

Laszlo J Mate, MD, PA

North Palm Beach, FL United States
  Connect »

Bioclinica Research

The Villages, FL United States
  Connect »

Boston Center Memory

Newton, MA United States
  Connect »

The NeuroCognitive Institute

Mount Arlington, NJ United States
  Connect »

UNC Hospital

Chapel Hill, NC United States
  Connect »

Insight Clinical Trials LLC

Shaker Heights, OH United States
  Connect »

Axon Clinical

Praha 5, Czechia
  Connect »

City Clinical Hospital #34

Novosibirsk, Russian Federation
  Connect »

Samara Psychiatric Hospital

Samara, Russian Federation
  Connect »

Clinic "Hundred Years"

Tomsk, Russian Federation
  Connect »

Neurology Practice

Pretoria, South Africa
  Connect »

ProScience

Culver City, CA United States
  Connect »

Accrescent Clinical, Inc.

Neptune, NJ United States
  Connect »

Wasatch Clinical Research

Salt Lake City, UT United States
  Connect »

Cognitive Clinical Trials

Gilbert, AZ United States
  Connect »

Axcess Medical Research

Loxahatchee Groves, FL United States
  Connect »

City Psychiatric Hospital #3

Saint Petersburg, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.